help button home button Endocrine Society Molecular Endocrinology ENDO 08 Sessions Library
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on December 6, 2007
Molecular Endocrinology, doi:10.1210/me.2007-0333
Molecular Endocrinology Vol. 0, No. 2007 200703331-
doi:10.1210/me.2007-0333
Copyright © 2007 by the Endocrine Society.
This Article
Right arrow Author Manuscript (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
22/3/737    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fretz, J. A.
Right arrow Articles by Pike, J. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fretz, J. A.
Right arrow Articles by Pike, J. W.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Substance via MeSH

Submitted on June 29, 2007
Accepted on November 27, 2007

RANKL-INDUCED NUCLEAR FACTOR OF ACTIVATED T CELLS (C1) AUTOREGULATES ITS OWN EXPRESSION IN OSTEOCLASTS AND MEDIATES THE UPREGULATION OF TARTRATE-RESISTANT ACID PHOSPHATASE

Jackie A. Fretz, Nirupama K. Shevde, Sujay Singh, Bryant G. Darnay, and J. Wesley Pike*

Department of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin 53706; IMGENEX Inc., San Diego, California 92120; and Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas 77030

* To whom correspondence should be addressed. E-mail: pike{at}biochem.wisc.edu.

Osteoclasts are large multinucleated, bone resorbing cells derived from hematopoietic precursors in response to RANKL. RANKL activates a number of signal transduction pathways which stimulate in turn a series of specific transcription factors that initiate the process of osteoclastogenesis. Perhaps the most important of these is NFATc1, a DNA binding protein that upon activation translocates to the nucleus where it stimulates transcription. The objective of this study was to explore the process whereby RANKL induces NFATc1 and to assess the role of this factor in the activation of an additional key osteoclast target gene. We found that while several NFAT members are expressed in RAW264.7 cells, sRANKL-induced upregulation is limited to NFATc1 through a mechanism that is largely autoregulatory. Thus, while we observed the presence of resident NFAT members at the inducible Nfatc1 P1 promoter at very early times following RANKL treatment, a selective and time-dependent increase in the binding of upregulated NFATc1 to Nfatc1 was observed beginning at 12 hr. Several additional factors that are activated by sRANKL and also participate in NFATc1 upregulation include c-fos and RNA polymerase II. ChIP analysis also revealed a similar, time-dependent accumulation of NFATc1 at multiple sites on the Acp5 promoter, thereby highlighting a central contributing role for NFATc1 in the activation of this gene as well. Our studies provide additional molecular detail regarding the mechanisms through which RANKL induces NFATc1 in osteoclast precursors and into mechanisms by which NFATc1-induces the expression of at least one gene responsible for the osteoclast phenotype.


Key words: RANKL • osteoclastogenesis • NFAT transcription factors • osteoclast genes • TRAP







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2007 by The Endocrine Society